小剂量拓扑替康联合顺铂治疗晚期肺鳞癌的临床研究

目的：观察小剂量拓扑替康联合顺铂治疗晚期肺鳞癌的疗效和毒副反应。方法：经病理组织学或细胞学证实的38例肺鳞癌患者给予拓扑替康0．8mg/m^2静滴，第1－5天，顺铂50－70mg/m^2静滴，第6天，21天为1周期，结果：全组无完全缓解，部分缓解17例，稳定15例，进展6例，27例初治者和11例复治者近期有效率分别为48．1％，36．4％，总有效率44．7％，中位生存期10个月（4－14个月），1年生存率为34．2％，毒副反应主要有骨髓抑制，胃肠道反应及轻度脱发，结论：小剂量拓扑替康联合顺铂治疗肺鳞癌具有较好的疗效，不良反应可耐受。

Clinical study of small dose of topotecan combined with cisplatin in the treatment of advanced squamous carcinoma of lung

Objective To evaluate the therapeutic efficacy and toxicity of the combination of topotecan and cisplatin in the treatment of patients with advanced sqamous carcinoma of lung. Methods Thirty eight patients with stage III or stage IV squamous carcinoma of lung confirmed pathohistologically or cytologically were administered intravenously with 0.8 mg/m 2 topotecan on day 1-5, and 50-70 mg/m 2 cisplatin on day 6 of the 21 day cycle. Results The total effective rate was 44.7%, among them 17 was partial responses, whereas 15 patients stable and 6 patients were progressive. The response rate of 27 patients without prior chemotherapy and 11 patients with chemotherapy was 48.1% and 36.4%, respectively. No significant difference was found between the two groups ( P >0.05). The median duration of survival was 10 months, and 1 year survival rate was 34.2%. The major responses to nonhematologic toxicity were nausea or vomiting and alopecia. Conclusion The combination of topotecan and cisplatin is a feasible, well tolerated and active scheme in treatment of advanced squamous carcinoma of lung.